Dendreon Makes Progress, but Issues May Loom

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Dendreon's (Nasdaq: DNDN  ) sales of its prostate cancer treatment, Provenge, haven't exactly lived up to expectations. The biotech is doing its best to raise U.S. sales and keep costs in check, but one way to get an instant boost in revenue is to start selling the treatment in Europe.

But first it has to be approved there. And because the drug has a complex manufacturing process, before that, Dendreon has to get its manufacturing plant approved.

The biotech announced on Thursday that it's making progress there; the first patient has been dosed in a trial of European men. This is an open-label study, meaning the patients know they're receiving Provenge, so we won't learn anything new about efficacy of Provenge.

The trial is simply to show that it can manufacture the individualized treatment. Dendreon has previously set up three manufacturing plants, one that it had to close, so this is a fairly low-risk step toward selling Provenge in Europe.

Once Provenge is approved in Europe, it'll likely run into the same challenges it's seeing in the U.S. Johnson & Johnson's (NYSE: JNJ  ) Zytiga and Sanofi's (NYSE: SNY  ) Jevtana are already on the market to treat prostate cancer in Europe. And Medivation (Nasdaq: MDVN  ) has applied for approval of Xtandi there. In addition to competition, Provenge's other issue -- cost -- will still be a problem in Europe, where centralized health care focuses on the cost-benefit ratio for drugs.

Dendreon's best solution might be to license out the European rights to Provenge for some upfront cash and a royalty on sales. The biotech won't make as much -- the pharma partner has to take a cut -- but it might not give up that much since a big pharma partner with a presence in the region would likely be able to keep expenses lower than Dendreon can. And in exchange for giving up some profits, Dendreon would alleviate risk since it won't have to shell out cash until the region becomes profitable. 

Dendreon may struggle in Europe, but these three American companies are set to dominate the world. Find out what they are and why Fool analysts like them so much in the Fool's free report. Click here now to claim your free copy.


Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2036274, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:37:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
MDVN $0.00 Down +0.00 +0.00%
Medivation CAPS Rating: ****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****